More than 4 out of 5 older women survivors of colorectal cancer may be experiencing a range of gastrointestinal symptoms many years after being diagnosed and treated, a new study suggests.
AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal – Pharmaceutical Technology
Share this article Along with Fusion’s pipeline of radioconjugates, AstraZeneca said the deal will bring new research and development (R&D) expertise and supply chain strengthening.